Patents by Inventor Guillaume Marcion

Guillaume Marcion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1
    Patent number: 10647752
    Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: May 12, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Medicale), Fondation Imagine, Assistance Publique-Hopitaux de Paris (APHP), Université Paris Descartes, Centre National de la Recherche Scientifique (CNRS), Université de Bourgogne, CNAM—Conservatoire National des Arts at Metier
    Inventors: Zakia Belaid-Choucair, Olivier Hermine, Matthieu Montes, Carmen Garrido-Fleury, Renaud Seigneuric, Guillaume Marcion
  • Polypeptides Capable of Inhibiting the Binding Between Leptin and Neuropilin-1
    Publication number: 20180230189
    Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.
    Type: Application
    Filed: September 21, 2016
    Publication date: August 16, 2018
    Inventors: Zakia Belaid-Choucair, Olivier Hermine, Matthieu Montes, Carmen Garrido-Fleury, Renaud Seigneuric, Guillaume Marcion
  • METHODS AND COMPOSITIONS FOR DIAGNOSING, MONITORING AND TREATING CANCER
    Publication number: 20170131285
    Abstract: The invention relates to methods for diagnosing cancer and determining the responsiveness to chemotherapyin a subject based on the detection of HSP70-expressing exosomes in a bodily fluid sample obtained from said subject. The invention also relates to methods for treating cancer and in particular methods for restoring or enhancing the anti-tumor immune response in a patient in need thereof by inhibiting the activation MDSC as well as methods for inhibiting or reducing HSP70-expressing exosomes-mediated tumor resistance against a chemotherapeutic agent and therefore methods for restoring or enhancing the efficacy of said chemotherapeutic agent.
    Type: Application
    Filed: June 12, 2015
    Publication date: May 11, 2017
    Inventors: Carmen Garrido-Fleury, Jessica Gobbo, Renaud Seigneuric, Guillaume Marcion